

Revisiting the personal protective equipment components of transmission-based precautions for the prevention of COVID-19 and other respiratory virus infections in healthcare

Diamantis Plachouras¹, Oliver Kacelnik², Jesús Rodríguez-Baño^{3,4}, Gabriel Birgand^{5,6}, Michael A Borg⁷, Brian Kristensen⁸, Jan Kubele⁹, Outi Lyytikäinen¹⁰, Elisabeth Presterl¹¹, Jacqui Reilly¹², Andreas Voss¹³, Walter Zingg^{14,15}, Carl Suetens¹, Dominique L Monnet¹

1. European Centre for Disease Prevention and Control, Stockholm, Sweden
2. Norwegian Institute of Public Health, Oslo, Norway
3. Infectious Diseases and Microbiology division, Hospital Universitario Virgen Macarena and Department of Medicine, University of Seville/CSIC, Biomedicine Institute of Seville, Seville, Spain
4. CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain
5. Regional Centre for Infection Prevention and Control, Region of Pays de la Loire, Nantes, France
6. Health Protection Research Unit, Healthcare Associated Infection and Antimicrobial Resistance, Imperial College London, London, United Kingdom
7. Infection Control Department, Mater Dei Hospital, Msida, Malta
8. Statens Serum Institut, Copenhagen, Denmark
9. Clinical Microbiology and ATB centre, Na Homolce Hospital, Prague, Czechia
10. Finnish Institute for Health and Welfare, Helsinki, Finland
11. Department for Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria
12. Research Centre for Health, Glasgow Caledonian University, Glasgow, United Kingdom
13. Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, Groningen, the Netherlands
14. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
15. Charité Universitätsmedizin, Berlin, Germany

Correspondence: Diamantis Plachouras (diamantis.plachouras@ecdc.europa.eu)

Citation style for this article:

Plachouras Diamantis, Kacelnik Oliver, Rodríguez-Baño Jesús, Birgand Gabriel, Borg Michael A, Kristensen Brian, Kubele Jan, Lyytikäinen Outi, Presterl Elisabeth, Reilly Jacqui, Voss Andreas, Zingg Walter, Suetens Carl, Monnet Dominique L. Revisiting the personal protective equipment components of transmission-based precautions for the prevention of COVID-19 and other respiratory virus infections in healthcare. *Euro Surveill.* 2023;28(32):pii=2200718. <https://doi.org/10.2807/1560-7917.ES.2023.28.32.2200718>

Article submitted on 30 Aug 2022 / accepted on 10 May 2023 / published on 10 Aug 2023

The COVID-19 pandemic highlighted some potential limitations of transmission-based precautions. The distinction between transmission through large droplets vs aerosols, which have been fundamental concepts guiding infection control measures, has been questioned, leading to considerable variation in expert recommendations on transmission-based precautions for COVID-19. Furthermore, the application of elements of contact precautions, such as the use of gloves and gowns, is based on low-quality and inconclusive evidence and may have unintended consequences, such as increased incidence of healthcare-associated infections and spread of multidrug-resistant organisms. These observations indicate a need for high-quality studies to address the knowledge gaps and a need to revisit the theoretical background regarding various modes of transmission and the definitions of terms related to transmission. Further, we should examine the implications these definitions have on the following components of transmission-based precautions: (i) respiratory protection, (ii) use of gloves and gowns for the prevention of respiratory virus infections, (iii) aerosol-generating procedures and (iv) universal

masking in healthcare settings as a control measure especially during seasonal epidemics. Such a review would ensure that transmission-based precautions are consistent and rationally based on available evidence, which would facilitate decision-making, guidance development and training, as well as their application in practice.

Background

Standard and transmission-based precautions are essential elements of infection prevention and control (IPC) practices [1,2]. Transmission-based precautions are applied in addition to standard precautions in patients suspected or confirmed to be infected or colonised with certain microorganisms. There are three types of transmission-based precautions, depending on the transmission route: contact, droplet and airborne precautions. Each type of precautions has implications for the use of personal protective equipment (PPE) and for administrative and engineering control measures such as the placement of the patient, staff cohorting and training and environmental cleaning. Contact precautions include the application of gloves

and gowns, droplet precautions require the use of medical face masks, and airborne precautions require the placement of the patient in an airborne precaution isolation room and the use of a well-fitted respirator by the staff [1]. Sometimes, transmission-based precautions are combined to ensure that multiple modes of transmission are addressed. For respiratory infections, two concepts of transmission through the air have been distinguished: short-range droplet transmission and long-range aerosol transmission. In the current transmission-based precautions, most respiratory viruses were considered as being transmitted primarily through large droplets and only in exceptional situations by aerosols, resulting in the widespread application of droplet precautions such as the use of a medical face masks, rather than precautions against airborne transmission [3,4]. The COVID-19 pandemic highlighted a potential limitation of the underpinning theory and application of transmission-based precautions as used during the past decades.

Evidence for transmission routes and respective precautions

Emerging scientific evidence and revisiting previously available studies support the argument that the distinction between droplets and aerosols is artificial, and dogmatic size thresholds for 'large droplets' and 'aerosols' are not fully consistent with the physical properties that are relevant for the transmission of respiratory viruses [5-7]. While some evidence of the contribution of aerosols to the transmission of respiratory viruses, such as influenza, has been available, airborne transmission of influenza is still debatable and has not been considered a primary route [8-10]. Accumulating evidence from the COVID-19 pandemic indicated that aerosols may play a role in the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [5,11], thus leading to a review of the recommendations such as ventilation and questioning the rationale for droplet precautions to prevent transmission of SARS-CoV-2.

Only a few microorganisms, such as *Mycobacterium tuberculosis*, and the measles and varicella-zoster viruses, have traditionally been considered as being transmitted obligatorily or preferentially through the airborne route, thus necessitating precautions against airborne transmission, including the use of respirators and hospitalisation in single rooms with negative pressure [2]. These recommendations are based on limited evidence of long-distance transmission to people not in close proximity to the case. Based on observational studies of severe acute respiratory syndrome (SARS), respiratory viruses have also been considered to be transmitted opportunistically through aerosols during procedures that are associated with increased production of infectious aerosols, although the evidence is weak and often contradictory [3,12].

Altogether, the relevant role of various routes of transmission, which includes the physical transport of an

infectious particle leading to infection, has been challenging to assess. Efforts to define criteria of proof for each transmission route have been useful but it is difficult to draw any conclusion with certainty [13,14]. The available evidence originates mostly from outbreak investigations and is rarely definitive proof of one route over another, as alternate explanations for transmission cannot be dismissed nor can the adherence to the protective measures be easily assessed. The persistence of viruses on environmental surfaces and aerosols has also been extensively tested [15]. Few human exposure studies have been performed to elucidate the route of transmission of some respiratory viruses, and the results have often been contradictory, and it is uncertain if they can be extrapolated to other viruses [14,16]. These results indicate that several routes contribute to the transmission of respiratory viruses, depending on various factors such as the viral loads, presence of virus in secretions, activities and behaviour of the infected and exposed persons. For example, singing is an activity that was associated with a well-documented SARS-CoV-2 outbreak in a choir, presumably through increased release of respiratory secretions [17]. In addition, differences in expelled viral loads have also been hypothesised as explanations of super-spreading events of SARS-CoV-2, where transmission was linked to a few highly infectious individuals [18].

Furthermore, the quality and certainty of evidence on the effectiveness of various elements of PPE used for transmission-based precautions remains low, as the evidence is based mostly on observational studies and only a few randomised controlled trials. Several systematic reviews and meta-analyses have been published but the certainty of the conclusions is limited by the bias of the underlying studies [19]. This means that guidance is, to a large extent, based on assumptions about the transmission routes, indirect evidence, feasibility, availability of resources and the precautionary principle. One example is the lack of convincing evidence in epidemiological studies or clinical trials that respirators should have a better protective effect against SARS-CoV-2 transmission than medical face masks, despite the better filtration efficacy and fitting of respirators [20-22]. Given these uncertainties, there has been considerable variation in expert recommendations on transmission-based precautions for COVID-19 in healthcare settings. One example of this is that some countries have opted for medical face masks, whereas other countries recommended respirators for the routine care of suspected and/or confirmed COVID-19 patients [23]. Because of the lack of evidence, individual values and preferences may play an important role in selecting the type of face mask, as also acknowledged in the guidance from the World Health Organization [24]. Furthermore, while transmission of SARS-CoV-2 through direct and indirect contact has not been demonstrated convincingly, replication-competent SARS-CoV-2 has been detected on environmental surfaces and objects [15]. Therefore, fomite transmission is considered possible and remains an important

Box

Proposed points for review and research gaps related to the transmission-based precautions framework for respiratory viral infections

- A review of the theoretical framework, and definitions of terms, for modes of transmission underpinning the IPC paradigm;
- Risk assessment parameters for IPC measures based on risk of infection transmission inclusive of: transmissibility of infection, impact of infection, patient factors, staff risk factors, practice/procedure factors and environmental factors, while taking into consideration: healthcare workers' preference, desirable and undesirable anticipated effects and the balance between them, overall certainty of the evidence of effects, acceptability and ease of implementation;
- Design and implementation of high-quality applied clinical research to inform: - The use of respirators and medical face masks in various risk scenarios, - The impact of gowns, aprons and eye protection as part of transmission-based precautions, - Optimal masking strategies to reduce risk of transmission inclusive of sessional vs risk-targeted, wider masking policy, including behavioural insights to adherence, any unintended consequences for staff and patient safety, and staff preferences, - A risk-based approach to the selection of personal protective equipment considering the time of exposure, the proximity to the patient and the procedure/task.

IPC: infection prevention and control.

consideration when deciding on the need for contact precautions, such as the use of gowns and gloves.

Later variants of SARS-CoV-2 are characterised by higher transmissibility than previous variants [25]. On the other hand, severity of disease has been reported to be lower, possibly related to intrinsic viral characteristics as well as higher population immunity due to vaccination and previous infection, and thereby better protection against severe disease. Nevertheless, patients in healthcare facilities are often vulnerable due to their age, comorbidities and immunosuppressive treatment. Transmission from COVID-19 cases (patients, staff members or visitors) is an ongoing risk, especially when the prevalence of COVID-19 in the community is high. During the pandemic, universal masking in healthcare settings (medical face mask for all persons – staff, patients, visitors, service providers and others – within the health facility, including primary, secondary and tertiary care levels, outpatient care and long-term care facilities) has been applied extensively to minimise this risk, although the evidence base for this measure remains weak [26]. Well-designed studies of the effectiveness of universal masking during winter epidemics of respiratory viral illnesses are required.

These observations indicate a need to revisit transmission-based precautions and their effectiveness for preventing transmission of SARS-CoV-2 in particular and other respiratory viruses in general, as well as a need to fund, design and execute high-quality studies to fill the evidence gaps for transmission-based precautions [27].

Which precautions do we need to revisit? Opinion of the ECDC expert panel

On 16 March 2022, the European Centre for Disease Prevention and Control (ECDC) convened a group of

11 IPC experts to explore whether modifications in transmission-based precautions would be needed to address what we learned during the COVID-19 pandemic and to identify knowledge gaps and research needs. Experts were selected as a convenience sample from the ECDC Expert Directory based on declared expertise in hygiene and infection control. The discussion was structured based on the following elements of the Evidence to Decision (EtD) framework [28]: (i) How substantial are the desirable anticipated effects? (ii) How substantial are the undesirable anticipated effects? (iii) What is the overall certainty of the evidence of effects? (iv) Does the balance between desirable and undesirable effects favour the option or the alternative? (v) Is the option acceptable to key stakeholders? (vi) Can the option be easily implemented? The following topics were discussed on the basis of lack of current consensus: (i) respiratory protection, (ii) use of gloves and gowns, (iii) aerosol-generating procedures and (iv) universal masking. Through online polling, the experts in the panel rated the EtD elements related to each of these topics. The results of the poll were used to guide the discussion. The group proposed that the following elements of the current transmission-based precautions be reviewed, ideally with support from well-designed applied clinical research (Box).

Respiratory protection

Given that neither the current droplet nor the airborne precautions address the role of aerosols at short distances, various options could be considered for adapting current transmission-based precautions. Droplet precaution measures could be expanded to address the theoretical risks linked to inhalation of short-range aerosols. A two-tiered risk-based approach could be applied, based on proximity, length of exposure, type of symptoms and type of care: (i) contacts with prolonged, close proximity to the patient, including the

performance of high-risk procedures, are associated with higher risk and justify the use of high-efficacy respiratory protection; (ii) for contacts without prolonged, close proximity to an infectious patient in adequately ventilated spaces, the effectiveness of medical face masks would be sufficient.

Gloves and gowns

Gloves are part of contact precautions that have been recommended for the prevention of the transmission of respiratory viruses such as influenza and SARS-CoV-2. However, hand hygiene, including alcohol-based hand rubs, is an effective measure against SARS-CoV-2 and other respiratory viruses [29,30], as well as other microorganisms causing healthcare-associated infections [31]. It is a key component of standard IPC precautions. Wearing gloves has not been demonstrated to be superior to hand hygiene and has been associated with poor hand hygiene practices [32,33]. Gowns or aprons are also recommended as a measure to prevent contamination of clothes with the potential risk of subsequent transmission. However, there is limited and low-quality evidence to support the effectiveness of gloves, gowns, and aprons for the prevention of respiratory tract infections or the superiority of gowns vs aprons [3,21,30,32,34-36]. Dedicated footwear or shoe covers are not recommended for routine care [37].

While the desirable anticipated effects from the use of gloves and gowns/aprons are small, the undesirable anticipated effects are at least moderate. Therefore, the balance of desirable and undesirable effects does not favour the routine use of gloves or gowns/aprons for the prevention of COVID-19 and other respiratory virus infections. An exception may be prolonged, close exposure to a case, especially a patient who is coughing or sneezing heavily, when high-risk procedures are required, or in cases when there is a high risk of exposure to infectious body fluids - as stipulated by standard precautions.

Aerosol-generating procedures

There is emerging evidence that the increased risk of infection from some aerosol-generating procedures may be more related to proximity with the patient than to increased generation of aerosols by the procedure itself [38]. Several studies have failed to demonstrate substantial aerosol generation linked to procedures such as intubation and extubation, for which the risk for transmission of respiratory viruses such as SARS had been shown to be high [39,40]. This suggests that the term 'aerosol-generating procedures' may be a misnomer and could be replaced by alternative terminologies such as 'high-risk procedures', to reflect this emerging evidence base. Further clinical research is needed to better describe the risks associated with these procedures and the role of aerosol generation in infection transmission.

Given that the risk of transmission is related not only to the microorganism, but also to the duration and

proximity of contact, the applied transmission-based precautions should ideally be selected following a point-of-care risk assessment, taking into account proximity, duration of exposure, risk of aerosol production and the type of task performed.

Universal masking

Various forms of continuous face mask use, such as universal masking, applying to healthcare workers, patients, visitors and persons accompanying the patient, and targeted continuous masking, applying to healthcare workers [26], especially during periods of high community transmission of respiratory viruses, such as the influenza season and during COVID-19 surges, are a potential measure to minimise healthcare-associated transmission of respiratory viruses [41]. The rationale for wearing a face mask includes both personal protection and source control, i.e. limiting the release of infectious respiratory particles by people who are infected and often asymptomatic or with limited symptoms. Given the risk of transmission of other respiratory viruses, such as influenza, and the role of other respiratory viruses in healthcare-associated pneumonia [42], it is likely that universal masking and targeted continuous masking could contribute towards preventing the transmission of other respiratory viruses in healthcare settings during seasonal epidemics.

Eye protection

The eyes have been identified as potential routes of entry for respiratory viruses either directly, by infection of the ocular mucosa, or by transfer to the nasopharynx through the nasolacrimal duct [43]. Available evidence shows that eye protection is effective in decreasing the risk of transmission [44].

Discussion

A limitation of the above suggestions is the low level of available evidence in epidemiological studies or clinical trials for the effectiveness of specific elements of transmission-based precautions, including elements of PPE. Emerging evidence may increase our certainty in the magnitude of their effectiveness. A better understanding of the physical processes of exposure does not automatically translate into more effective prevention measures, as infection is a more complicated process than the transfer of infectious particles, involving immune processes and the suitability of various exposed host tissues for the entry of viruses. The applied preventive measures aim at mitigating the risk of infection to an acceptable level, taking into account the assessed risk but also other parameters such as preferences, ease of implementation and unintended consequences. Studies which use various forms of modelling and laboratory experiments to investigate the role of procedures and behaviours in generating and dispersing respiratory particles are limited and ultimately do not provide adequate evidence to address transmission in the complex healthcare environment. There is a need for applied clinical

research on the effectiveness but also the unintended consequences of preventive measures to support the development of evidence-based recommendations for guidance. Furthermore, human challenge studies, taking carefully into consideration any ethical issues [45], may provide valuable insights in the relative contribution of various routes of transmission and the effectiveness of PPE [46].

Transmission-based precautions are important but are not the only measures to control SARS-CoV-2 transmission in healthcare. It should be noted that PPE is only one among several control measures in the hierarchy that includes elimination and substitution, engineering and administrative controls [47]. Transmission of SARS-CoV-2 can occur before the primary case is suspected or diagnosed and a person can be more infectious at the early stages of disease. Once the clinical condition deteriorates – usually after the first week of disease – and the patient presents to hospital, the amount of shed SARS-CoV-2 is usually reduced, and the patient is consequently less infectious [48]. However, the duration of infectiousness can be affected by factors such as an immunocompromised state [49], severity of disease [50] and previous vaccination or infection [51]. The highest risk for the transmission of SARS-CoV-2 in healthcare comes from unidentified cases during periods of high community prevalence, which can be addressed by high index of suspicion and timely testing to guide the application of preventive measures. Finally, healthcare workers more often get infected through unprotected interactions with colleagues, family members and other private contacts [36]. Several other factors may influence the effectiveness of PPE, including the fit of face masks and respirators [52] and breaches in their proper use. All these points indicate that control of SARS-CoV-2 transmission in healthcare facilities will remain a challenge even after further optimisation of transmission-based precautions.

Measures to prevent and control an infection with high morbidity and case fatality and without treatment options are influenced by the assessed risk of adverse outcome [53] and often include additional PPE such as head covers, shoe covers or coveralls despite limited evidence of effectiveness. Such additional PPE reduces wearer comfort and is linked to a greater likelihood of self-contamination during PPE removal [54]. The same applies to emerging infections with a high likelihood of transmission. The role of the assessed risk in the selection of IPC measures is not reflected in the current definitions of transmission-based precautions, which is based on a mechanistic approach to transmission routes. Any revision of the transmission-based precautions should ideally make this point explicit.

Conclusion

The ECDC expert panel suggested that the IPC community should consider revisiting the current transmission-based precaution framework, including the theoretical background regarding various modes of transmission

and the definitions of terms related to transmission, to account for available and emerging scientific evidence and the role that the consequence of infection plays on the choice of the precautions. Such a review would ensure that transmission-based precautions are consistent and rationally based on available evidence, which would facilitate decision-making, guidance development and training, as well as their application in practice to prevent transmission of SARS-CoV-2 and of other respiratory viruses. High-quality studies are imperative to address the current knowledge gaps and strengthen the evidence for any future revision of transmission-based precautions.

Ethical statement

Not applicable because the work did not involve any data collection from people.

Conflict of interest

None declared.

Authors' contributions

DP, OK, CS and DM initiated and developed the concept of this perspective article. DP coordinated the work of the expert group and drafted the manuscript. OK, JRB, GB, MAB, BK, JK, OL, EP, JR, AV and WZ contributed to the development of the content as members of the expert group. OK, JRB, GB, MAB, BK, JK, OL, EP, JR, AV, WZ, CS and DM reviewed and contributed to drafts of the manuscript.

References

1. World Health Organization (WHO). Prevention of hospital-acquired infections: a practical guide. 2nd ed. Duclou G, Fabry J, Nicolle L, editors. Geneva: WHO; 2002. Available from: <https://apps.who.int/iris/handle/10665/67350>
2. Siegel JD, Rhinehart E, Jackson M, Chiarello R, the Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Atlanta: CDC; 2007. Available from: <https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html>
3. World Health Organization (WHO). Infection prevention and control of epidemic- and pandemic-prone acute respiratory diseases in health care. Geneva: WHO; 2014. Available from: <https://apps.who.int/iris/rest/bitstreams/515717/retrieve>
4. Roy CJ, Milton DK. Airborne transmission of communicable infection--the elusive pathway. *N Engl J Med*. 2004;350(17):1710-2. . Available from: <https://www.ncbi.nlm.nih.gov/pubmed/15102996> <https://doi.org/10.1056/NEJMp048051> PMID: 15102996
5. Tang JW. SARS-CoV-2 and aerosols-Arguing over the evidence. *J Virol Methods*. 2021;289:114033. <https://doi.org/10.1016/j.jviromet.2020.114033> PMID: 33285192
6. Randall K, Ewing ET, Marr LC, Jimenez JL, Bourouiba L. How did we get here: what are droplets and aerosols and how far do they go? A historical perspective on the transmission of respiratory infectious diseases. *Interface Focus*. 2021;11(6):20210049. <https://doi.org/10.1098/rsfs.2021.0049> PMID: 34956601
7. Association for Aerosol Research. Position paper of the Gesellschaft für Aerosolforschung on understanding the role of aerosol particles in SARS-CoV-2 infection. Köln: Gesellschaft für Aerosolforschung; 2020. Available from: https://www.info.gaef.de/_files/ugd/fab12b_ob691414cfb344fe96d4b44e6f44a5ab.pdf
8. Tellier R. Review of aerosol transmission of influenza A virus. *Emerg Infect Dis*. 2006;12(11):1657-62. <https://doi.org/10.3201/eid1211.060426> PMID: 17283614

9. Tellier R. Aerosol transmission of influenza A virus: a review of new studies. *J R Soc Interface*. 2009;6(Suppl 6) Suppl 6:S783-90. <https://doi.org/10.1098/rsif.2009.0302.focus> PMID: 19773292
10. Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza A in human beings. *Lancet Infect Dis*. 2007;7(4):257-65. [https://doi.org/10.1016/S1473-3099\(07\)70029-4](https://doi.org/10.1016/S1473-3099(07)70029-4) PMID: 17376383
11. van der Valk JPM, In 't Veen JCCM. SARS-Cov-2: the relevance and prevention of aerosol transmission. *J Occup Environ Med*. 2021;63(6):e395-401. <https://doi.org/10.1097/JOM.0000000000002193> PMID: 33871953
12. Leal J, Farkas B, Mastikhina L, Flanagan J, Skidmore B, Salmon C, et al. Risk of transmission of respiratory viruses during aerosol-generating medical procedures (AGMPs) revisited in the COVID-19 pandemic: a systematic review. *Antimicrob Resist Infect Control*. 2022;11(1):102. <https://doi.org/10.1186/s13756-022-01133-8> PMID: 35953854
13. Jefferson T, Heneghan CJ, Spencer E, Brassey J, Plüddemann A, Onakpoya I, et al. A hierarchical framework for assessing transmission causality of respiratory viruses. *Viruses*. 2022;14(8):1605. <https://doi.org/10.3390/v14081605> PMID: 35893670
14. Gwaltney JM Jr, Hendley JO. Rhinovirus transmission: one if by air, two if by hand. *Am J Epidemiol*. 1978;107(5):357-61. <https://doi.org/10.1093/oxfordjournals.aje.a112555> PMID: 208415
15. Onakpoya IJ, Heneghan CJ, Spencer EA, Brassey J, Rosca EC, Maltoni S, et al. Viral cultures for assessing fomite transmission of SARS-CoV-2: a systematic review and meta-analysis. *J Hosp Infect*. 2022;130:63-94. <https://doi.org/10.1016/j.jhin.2022.09.007> PMID: 36115620
16. Dick EC, Jennings LC, Mink KA, Wartgow CD, Inhorn SL. Aerosol transmission of rhinovirus colds. *J Infect Dis*. 1987;156(3):442-8. <https://doi.org/10.1093/infdis/156.3.442> PMID: 3039011
17. Hamner L, Dubbel P, Capron I, Ross A, Jordan A, Lee J, et al. High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(19):606-10. <https://doi.org/10.15585/mmwr.mm6919e6> PMID: 32407303
18. Chen PZ, Koopmans M, Fisman DN, Gu FX. Understanding why superspreading drives the COVID-19 pandemic but not the H1N1 pandemic. *Lancet Infect Dis*. 2021;21(9):1203-4. [https://doi.org/10.1016/S1473-3099\(21\)00406-0](https://doi.org/10.1016/S1473-3099(21)00406-0) PMID: 34352224
19. Murad MH, Asi N, Alsawas M, Alahadab F. New evidence pyramid. *Evid Based Med*. 2016;21(4):125-7. <https://doi.org/10.1136/ebmed-2016-110401> PMID: 27339128
20. Chou R, Dana T, Jungbauer R, Weeks C, McDonagh MS. Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings: a living rapid review. *Ann Intern Med*. 2020;173(7):542-55. <https://doi.org/10.7326/M20-3213> PMID: 32579379
21. Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. *Cochrane Database Syst Rev*. 2020;11(11):CD006207. PMID: 33215698
22. Loeb M, Bartholomew A, Hashmi M, Tarhuni W, Hassany M, Youngster I, et al. Medical masks versus N95 respirators for preventing COVID-19 among health care workers: a randomized trial. *Ann Intern Med*. 2022;175(12):1629-38. <https://doi.org/10.7326/M22-1966> PMID: 36442064
23. Birgand G, Mutters NT, Otter J, Eichel VM, Lepelletier D, Morgan DJ, et al. Variation of national and international guidelines on respiratory protection for health care professionals during the COVID-19 pandemic. *JAMA Netw Open*. 2021;4(8):e2119257. <https://doi.org/10.1001/jamanetworkopen.2021.19257> PMID: 34347062
24. World Health Organization (WHO). Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline. Geneva: WHO; 2023. Available from: <https://apps.who.int/iris/bitstream/handle/10665/365576/WHO-2019-nCoV-ipc-guideline-2023.1-eng.pdf>
25. Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, Møller CH, Skov RL, et al. Household transmission of the SARS-CoV-2 Omicron variant in Denmark. *Nat Commun*. 2022;13(1):5573. <https://doi.org/10.1038/s41467-022-33328-3> PMID: 36151099
26. World Health Organization (WHO). Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed Geneva: WHO; 2021. Available from: <https://apps.who.int/iris/bitstream/handle/10665/342620/WHO-2019-nCoV-IPC-2021.1-eng.pdf?sequence=1&isAllowed=y>
27. Glasziou PP, Michie S, Fretheim A. Public health measures for covid-19. *BMJ*. 2021;375(2729):n2729. <https://doi.org/10.1136/bmj.n2729> PMID: 34789507
28. Moberg J, Oxman AD, Rosenbaum S, Schünemann HJ, Guyatt G, Flottorp S, et al. The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. *Health Res Policy Syst*. 2018;16(1):45. <https://doi.org/10.1186/s12961-018-0320-2> PMID: 29843743
29. Kratzel A, Todt D, V'kovski P, Steiner S, Gultom M, Thao TTN, et al. Inactivation of severe acute respiratory syndrome coronavirus 2 by WHO-recommended hand rub formulations and alcohols. *Emerg Infect Dis*. 2020;26(7):1592-5. <https://doi.org/10.3201/eid2607.200915> PMID: 32284092
30. Jefferson T, Dooley L, Ferroni E, Al-Ansary LA, van Driel ML, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. *Cochrane Database Syst Rev*. 2023;1(1):CD006207. PMID: 36715243
31. World Health Organization (WHO). Guidelines on hand hygiene in health care. Geneva: WHO; 2009. Available from: <https://apps.who.int/iris/rest/bitstreams/52455/retrieve>
32. Fuller C, Savage J, Besser S, Hayward A, Cookson B, Cooper B, et al. "The dirty hand in the latex glove": a study of hand hygiene compliance when gloves are worn. *Infect Control Hosp Epidemiol*. 2011;32(12):1194-9. <https://doi.org/10.1086/662619> PMID: 22080658
33. Cusini A, Nydegger D, Kaspar T, Schweiger A, Kuhn R, Marschall J. Improved hand hygiene compliance after eliminating mandatory glove use from contact precautions-Is less more? *Am J Infect Control*. 2015;43(9):922-7. <https://doi.org/10.1016/j.ajic.2015.05.019> PMID: 26122873
34. Loveday HP, Wilson JA, Pratt RJ, Golsorkhi M, Tingle A, Bak A, et al. epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. *J Hosp Infect*. 2014;86(Suppl 1):S1-70. [https://doi.org/10.1016/S0195-6701\(13\)60012-2](https://doi.org/10.1016/S0195-6701(13)60012-2) PMID: 24330862
35. Meda M, Gentry V, Reidy P, Garner D. Unintended consequences of long-sleeved gowns in a critical care setting during the COVID-19 pandemic. *J Hosp Infect*. 2020;106(3):605-9. <https://doi.org/10.1016/j.jhin.2020.07.036> PMID: 32745589
36. Belan M, Charmet T, Schaeffer L, Tubiana S, Duval X, Lucet JC, et al. SARS-CoV-2 exposures of healthcare workers from primary care, long-term care facilities and hospitals: a nationwide matched case-control study. *Clin Microbiol Infect*. 2022;28(11):1471-6. <https://doi.org/10.1016/j.cmi.2022.05.038> PMID: 35777605
37. Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Scotland Infection Control Team. Standard infection control precautions. Literature review. Personal protective equipment (PPE) footwear. Edinburgh: Public Health Scotland; 2021. Available from: <https://www.nipcm.hps.scot.nhs.uk/media/1901/2021-07-22-ppe-footwear-v30-final.pdf>
38. Wilson NM, Marks GB, Eckhardt A, Clarke AM, Young FP, Garden FL, et al. The effect of respiratory activity, non-invasive respiratory support and facemasks on aerosol generation and its relevance to COVID-19. *Anaesthesia*. 2021;76(11):1465-74. <https://doi.org/10.1111/anae.15475> PMID: 33784793
39. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. *PLoS One*. 2012;7(4):e35797. <https://doi.org/10.1371/journal.pone.0035797> PMID: 22563403
40. National Health Service (NHS) England. A rapid review of aerosol generating procedures (AGPs). Leeds: NHS England. 2022. Available from: https://www.england.nhs.uk/wp-content/uploads/2022/04/C1632_rapid-review-of-aerosol-generating-procedures.pdf
41. World Health Organization (WHO). Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline. Geneva: WHO; 2023. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-ipc-guideline-2022.2>
42. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Viruses are prevalent in non-ventilated hospital-acquired pneumonia. *Respir Med*. 2017;122:76-80. <https://doi.org/10.1016/j.rmed.2016.11.023> PMID: 27993295
43. Coroneo MT, Collignon PJ. SARS-CoV-2: eye protection might be the missing key. *Lancet Microbe*. 2021;2(5):e173-4. [https://doi.org/10.1016/S2666-5247\(21\)00040-9](https://doi.org/10.1016/S2666-5247(21)00040-9) PMID: 33655228
44. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet*. 2020;395(10242):1973-87. [https://doi.org/10.1016/S0140-6736\(20\)31142-9](https://doi.org/10.1016/S0140-6736(20)31142-9) PMID: 32497510
45. Jamrozik E, Selgelid MJ. COVID-19 human challenge studies: ethical issues. *Lancet Infect Dis*. 2020;20(8):e198-203. [https://doi.org/10.1016/S1473-3099\(20\)30438-2](https://doi.org/10.1016/S1473-3099(20)30438-2) PMID: 32479747

46. Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. *Nat Med.* 2022;28(5):1031-41. <https://doi.org/10.1038/s41591-022-01780-9> PMID: 35361992
47. Centers for Disease Control and Prevention (CDC). Hierarchy of controls. Atlanta: CDC. [Accessed: 28 Feb 2023]. Available from: <https://www.cdc.gov/niosh/topics/hierarchy/default.html>
48. Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. *Nat Rev Microbiol.* 2023;21(3):147-61. PMID: 36460930
49. Jefferson T, Spencer EA, Conly JM, Rosca EC, Maltoni S, Brassey J, et al. Viral cultures, cycle threshold values and viral load estimation for assessing SARS-CoV-2 infectiousness in haematopoietic stem cell and solid organ transplant patients: a systematic review. *J Hosp Infect.* 2023;132:62-72. <https://doi.org/10.1016/j.jhin.2022.11.018> PMID: 36473552
50. Nomura T, Kitagawa H, Omori K, Shigemoto N, Kakimoto M, Nazmul T, et al. Duration of infectious virus shedding in patients with severe coronavirus disease 2019 who required mechanical ventilation. *J Infect Chemother.* 2022;28(1):19-23. <https://doi.org/10.1016/j.jiac.2021.09.006> PMID: 34538728
51. Jung J, Kim JY, Park H, Park S, Lim JS, Lim SY, et al. Transmission and infectious SARS-CoV-2 shedding kinetics in vaccinated and unvaccinated individuals. *JAMA Netw Open.* 2022;5(5):e2213606. <https://doi.org/10.1001/jamanetworkopen.2022.13606> PMID: 35608859
52. Knobloch JK, Franke G, Knobloch MJ, Knobling B, Kampf G. Overview of tight fit and infection prevention benefits of respirators (filtering face pieces). *J Hosp Infect.* 2023;134:89-96. <https://doi.org/10.1016/j.jhin.2023.01.009> PMID: 36738992
53. Jones RM, Bleasdale SC, Maita D, Brosseau LM, CDC Prevention Epicenters Program. A systematic risk-based strategy to select personal protective equipment for infectious diseases. *Am J Infect Control.* 2020;48(1):46-51. <https://doi.org/10.1016/j.ajic.2019.06.023> PMID: 31358421
54. Chughtai AA, Chen X, Macintyre CR. Risk of self-contamination during doffing of personal protective equipment. *Am J Infect Control.* 2018;46(12):1329-34. <https://doi.org/10.1016/j.ajic.2018.06.003> PMID: 30029796

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2023.